Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday. The report from AARP Public Policy Institute said average list prices on these 25 drugs have nearly doubled since they hit the market and collectively cost Medicare ‒ and therefore American taxpayers ‒ nearly $50 billion in 2022.

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and uncertainty about a process largely held behind closed doors, just as another round of talks begin in the coming weeks under a new administration.

AARP's new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing Medicare to negotiate prices.

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, 46brooklyn Research, an Ohio non-profit focused on U.S. drug pricing data, said in a report on Thursday.

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit, enrollees are responsible for 25 percent of their dr